SCHEMBL172701

SCHEMBL172701

CC[C@H](N)C(=O)OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL918471 1.00
SCHEMBL1288233 1.00
Hydrochloric Acid SCHEMBL349149 0.97
Hydrochloric Acid SCHEMBL2029151 0.97
Hydrochloric Acid SCHEMBL28273537 0.97 CA1 (0.43)
SCHEMBL18833452 0.97
Hydrochloric Acid SCHEMBL1064128 0.97
Hydrochloric Acid SCHEMBL28666579 0.97 CA1 (0.43)
Water SCHEMBL28662108 0.97
Hydrochloric Acid SCHEMBL28273538 0.97 CA1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114634437-B Simple preparation method of brivaracetam 武汉氟本氘合新材料科技有限公司 2023-05-30 CN claimed
CN-112195203-B Method for synthesizing (S) -2-aminobutanamide by enzyme method 江苏八巨药业有限公司 2022-07-26 CN claimed
CN-114634437-A Simple preparation method of brivaracetam 武汉氟本氘合新材料科技有限公司 2022-06-17 CN claimed
CN-112195203-A Method for synthesizing (S) -2-aminobutanamide by enzyme method 江苏八巨药业有限公司 2021-01-08 CN claimed
CN-109134341-A A kind of preparation method of Levetiracetam 黑龙江珍宝岛药业股份有限公司 2019-01-04 CN claimed
JP-4511835-B2 2010-07-28 JP claimed
EP-1442050-A2 LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF MALESCI ISTITUTO FARMACOBIOLOGICO S.p.A. (IT) 2004-08-04 EP claimed
WO-2003037916-A2 LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) 2003-05-08 WO claimed
US-20260008787-A1 FUSED RING KRAS INHIBITORS FOR TREATING DISEASE BLOSSOMHILL THERAPEUTICS INC (US) 2026-01-08 US disclosed
EP-4021901-B1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2025-09-24 EP disclosed
EP-4551577-A1 FUSED RING KRAS INHIBITORS FOR TREATING DISEASE Blossomhill Therapeutics, Inc. (US) 2025-05-14 EP disclosed
CN-119790058-A Fused cyclic KRAS inhibitors for the treatment of diseases 荣山医药股份有限公司 2025-04-08 CN disclosed
US-20240400563-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY 2024-12-05 US disclosed
WO-2024151638-A2 COMPOUNDS FOR FGFRS INHIBITORS COGENT BIOSCIENCES, INC. (US) 2024-07-18 WO disclosed
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed
WO-2006095362-A1 PROCESS FOR PREPARING LEVETIRACETAM RUBAMIN LIMITED (IN) 2006-09-14 WO disclosed
US-20050059827-A1 Process for the preparation of valsartan and intermediates thereof TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) 2005-03-17 US disclosed
US-20050059827-A1 Process for the preparation of valsartan and intermediates thereof TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) 2005-03-17 US disclosed
WO-2004101534-A1 A METHOD OF PREPARATION OF N-(1-OXOPENTYL)-N-[[2'-(1H-TETRAZOL-5-y1) [1,1'-BIPHENYL] -4-y1]METHYL]-L-VALINE (VALSARTAN) ZENTIVA, A. S. (CZ) 2004-11-25 WO disclosed
CN-1376143-A Carboxylic acid derivatives and adhesion molecule inhibitors containing the same as the active ingredient TORAY INDUSTRIES (JP) 2002-10-23 CN disclosed